Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Peer Tfelt-Hansen Clear advanced filters

  • According to a new systematic review, placebo treatment in clinical trials of migraine prophylaxis results in responder rates ranging from 0–56%, probably owing to variable combinations of spontaneous improvement and genuine placebo effects. Clinicians who treat patients with migraine should be aware of the potential nonspecific effects of any treatment modality.

    • Peer C. Tfelt-Hansen
    • Anders Hougaard
    News & Views
    Nature Reviews Neurology
    Volume: 10, P: 10-11

  • In April 2012, the American Academy of Neurology and the American Headache Society issued new guidelines on preventive treatment for episodic migraine. Although the guidelines provide valuable information regarding drug efficacy, they do not address the equally important issue of adverse events.

    • Peer C. Tfelt-Hansen
    • Anders Hougaard
    News & Views
    Nature Reviews Neurology
    Volume: 8, P: 419-421

  • Results from a phase III trial have set zavegepant as the first intranasal gepant to be approved by the FDA for the acute treatment of migraine. The therapeutic benefits were modest, however, and more work is needed to address unmet treatment needs.

    • Håkan Ashina
    • Peer Tfelt-Hansen
    News & Views
    Nature Reviews Neurology
    Volume: 19, P: 329-330